Clindamycin Phosphate Patent Expiration

Clindamycin Phosphate was first introduced by Pfizer Inc in its drug Cleocin Phosphate on Approved Prior to Jan 1, 1982. Other drugs containing Clindamycin Phosphate are Clindesse, Cleocin, Cleocin Phosphate In Dextrose 5% In Plastic Container, Clindamycin Phosphate In 0.9% Sodium Chloride, Evoclin, Clindamycin Phosphate In Dextrose 5%, Xaciato, Clindagel, Cleocin T, Clindamycin Phosphate In Dextrose 5% In Plastic Container. 47 different companies have introduced drugs containing Clindamycin Phosphate.


Clindamycin Phosphate Patents

Given below is the list of patents protecting Clindamycin Phosphate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Xaciato US11129896 Topical formulations and treatments Sep 22, 2036 Organon Llc
Xaciato US12303563 Topical formulations and treatments Sep 22, 2036 Organon Llc
Clindesse US9789057 Pharmaceutical delivery system Dec 02, 2026 Padagis Us
Evoclin US7141237 Pharmaceutical foam Feb 03, 2024

(Expired)

Norvium Bioscience
Evoclin US7374747 Pharmaceutical foam Jan 23, 2024

(Expired)

Norvium Bioscience
Clindesse US6899890 Bioadhesive drug delivery system Apr 27, 2023

(Expired)

Padagis Us
Clindagel US6387383 Topical low-viscosity gel composition Aug 03, 2020

(Expired)

Bausch
Cleocin US6495157 Intravaginal clindamycin ovule composition Jul 20, 2020

(Expired)

Pfizer
Clindesse US5993856 Pharmaceutical preparations and methods for their administration Nov 17, 2017

(Expired)

Padagis Us



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Clindamycin Phosphate's patents.

Given below is the list recent legal activities going on the following patents of Clindamycin Phosphate.

Activity Date Patent Number
Patent litigations
Change in Power of Attorney (May Include Associate POA) 29 Dec, 2021 US11129896
Email Notification 29 Dec, 2021 US11129896
Correspondence Address Change 27 Dec, 2021 US11129896
Patent Issue Date Used in PTA Calculation 28 Sep, 2021 US11129896
Recordation of Patent Grant Mailed 28 Sep, 2021 US11129896
Email Notification 09 Sep, 2021 US11129896
Issue Notification Mailed 08 Sep, 2021 US11129896
Application Is Considered Ready for Issue 25 Aug, 2021 US11129896
Dispatch to FDC 25 Aug, 2021 US11129896
Issue Fee Payment Verified 23 Aug, 2021 US11129896


Clindamycin Phosphate's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Clindamycin Phosphate Generic API Manufacturers

Several generic applications have been filed for Clindamycin Phosphate. The first generic version for Clindamycin Phosphate was by Pharmacia And Upjohn Co and was approved on Approved Prior to Jan 1, 1982. And the latest generic version is by Carnegie Pharmaceuticals Llc and was approved on Jun 13, 2025.

Given below is the list of companies who have filed for Clindamycin Phosphate generic, along with the locations of their manufacturing plants worldwide.